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Salvianolic acid B (SA-B) is water-soluble component of Radix Salvia miltiorrhiza. The previous work indicated that SA-B can
inhibitMAPKandSmadsignalinginactivatedhepaticstellatecells(HSCs)toperformanti-ﬁbroticactivityLvetal.2010.However,
some studies have shown that there is cross-talk between MAPK and Smad in certain cell types. Thus, the anti-ﬁbrotic action of
SA-B may be through the cross-talk. In order to clarify the mechanism of SA-B further, we knocked down Smad in LX-2 cells
(SRV4) via RNAi, and then added TGF-β1, and PD98059 or SB203580 and SA-B. The levels of p-MEK and p-p38 were inhibited
by SA-B in SRV4 independent of TGF-β1. The expression of Col I and α-SMA in SRV4 could be reduced by SA-B independent
TGF-β1. SB203580 had not signiﬁcant eﬀect on p-MEK in SRV4 stimulated by TGF-β1. The levels of p-MEK in SRV4 were not
increased signiﬁcantly after TGF-β1 stimulation. PD98059 had no eﬀect on the levels of p-p38 in SRV4 irrespective of TGF-β1. In
conclusion, SA-B inhibits the synthesis of Col I in LX-2 cells independent of TGF-β1 stimulation, and the anti-ﬁbrotic eﬀect of
SA-B is due to direct inhibition of p38 signaling and inhibition the cross-talk of Smad to ERK signaling.
1.Introduction
Hepatic ﬁbrosis is a wound-healing response to chronic liver
injury. It is a scarring process associated with an increased
deposition of ﬁbrillar extracellular matrix in liver [1]. Much
progress has been made in understanding the cellular mech-
anisms of hepatic ﬁbrosis. Activation of HSCs is the central
event in this condition [2]. Following liver injury of any
etiology, HSCs undergo a transition from quiescent vitamin
A-rich cells into proliferative, ﬁbrogenic, and contractile
myoﬁbroblasts, in which synthesis of ECM and particularly
Col. I predominates [3].
Transforming growth factor β1( T G F - β1) is one of the
most powerful and widely distributed proﬁbrogenic medi-
ators. It is the dominant stimulator of ECM production
by HSCs, regulating deposition of the ECM as part of the
normal response to tissue injury and pathological ﬁbrosis [4,
5]. Alterations in TGF-homeostasis are important factors in
ﬁbroticdiseasesofmultipletissues.Thepathogenicrelevance
of TGF-β1 to hepatic ﬁbrosis has been established and the
signalingpathwayinducedbyTGF-β1inHSCsisfullyunder-
stood. It is clear that MAPK and Smad signaling pathways in
HSCs activated by TGF-β1l e a dt oe x c e s sE C Md e p o s i t i o n .
However, up to now, there are not eﬀective measures to stop
or reverse the disease progression.
In recent years, increasing attention has been directed
to the anti-ﬁbrotic activity of natural herbs, in particular
Salviae miltiorrhiza, a traditional Chinese herbal medicine
widely used for anti-ﬁbrosis in clinics. In order to explore
the mechanism of action of Salvia miltiorrhiza, Salvianolic
acids B (SA-B), an eﬀective water-soluble component of
Radix Salvia miltiorrhiza, was investigated. Previous research2 Evidence-Based Complementary and Alternative Medicine
indicated that SA-B could eﬀectively reverse liver ﬁbrosis in
patients suﬀering from chronic hepatitis B, and it was more
eﬀective than IFN-γ in reducing serum HA, PC-III, Col. IV,
and LM contents and decreasing ultrasound ﬁbrosis imaging
scores [6]. SA-B inhibits TGF-β1 secretion in activated HSCs
and inhibits the expression of Col. I stimulated by TGF-
β1. SA-B inhibits the Smad and MAPK pathway in HSCs
stimulated with TGF-β1[ 7, 8].
It has been reported that a synergy between TGF-β1
activated extracellular signal-regulated kinase (ERK) and
Smad signaling in collagen production by human glomeru-
lar mesangial cells, and dominant negative ERK blockade
reduced TGF-β1 induced phosphorylation of Smad2/3. This
eﬀect was not seen in the mouse mammary epithelial
NMuMG cell line, indicating that ERK-dependent activation
of Smad2/3 occurs only in certain cell types [9, 10]. These
results indicate that ERK-dependent R-Smad (receptor-reg-
ulated Smad) linker region phosphorylation enhances col-
lagen I synthesis and imply positive cross-talk between the
ERKandSmadpathwaysinhumanmesangialcells.However,
it is not clear if there is a cross-talk between MAPK and
Smad signaling pathways in TGF-β1-stimulated HSCs. Thus,
in order to clarify the targets of SA-B on anti-ﬁbrotic action,
the cross-talk would have to be inhibited.
This study investigated the anti-ﬁbrotic role of SA-B in
HSCs via inhibiting the Smad and MAPK signaling pathways
or by inhibiting the cross-talk between them.
2.MaterialsandMethods
2.1. Reagents. Smad4 polyclonal antibody, p-p38 mono-
clonalantibody,p38,p-MEKandMEKmonoclonalantibody
were purchased from Cell Signaling Technology (Beverly,
MA,USA);mouseanti-humanα-SMAmonoclonalantibody
and Trizol reagent were purchased from Sigma (St Louis,
MO, USA). BLOCK-iT Pol II miR RNAi expression vector
was purchased from Invitrogen (Carlsbad, CA, USA). Rabbit
anti-human type I collagen antibody, SB203580 (p38 signal-
ing inhibitor) and PD98059 (ERK signaling inhibitor) were
purchased from Chemicon (Temecula, CA, USA). Mouse
anti-GAPDH monoclonal antibody was purchased from
Sigma (St Louis, MO, USA) and TGF-β1w a ss u p p l i e db y
R&D Systems (Minneapolis, MN, USA). The human Type I
Collagen Detection Kit was purchased from Chondrex (Red-
mond, WA) and SA-B (purity > 98%; molecular formula:
C36H30O16; molecular weight: 718.62) was kindly provided
by Dr. Zhu Dayuan(Shanghai Institute of Materia Medica,
Shanghai, China). SA-B powder was stored at 4◦C. SA-B was
dissolved before use.
2.2. RNA Silencing and Cell Transfection. RNA silencing was
performed using the BLOCK-iT Pol II RNAi expression
vector kit following the manufacturer’s protocol. Artiﬁ-
cial Smad4 microRNA (miRNA) was cloned in pcDNA
6.2-GW/EmGFP-miR leading to cocistronic expression of
Emerald GFP (EmGFP) with miRNA of Smad4. Diﬀerent
sequences of Smad4 miRNA were designed using an algo-
rithm developed by Invitrogen. Sense and antisense DNA
sequences were SR1-Forward: TGC TGT ATG ATG GTA AGT
AGC TGG CTG TTT TGG CCA CTG ACT GAC AG CCA
GCT TTA CCA TCA TA and SR1-Reverse: CCT GTA TGA
TGG TAA AGC TGG CTG TCA GTC AGT GGC CAA AAC
A G CC A GC T AC T TA C CA T CA T AC ; SR2-Forward: TGC
TGT GGT GAG GCA AAT TAG GTG TGG TTT TGG CCA
CTG ACT GAC CAC ACC TAT TGC CTC ACC A and SR2-
Reverse: CCT GTG GTG AGG CAA TAG GTG TGG TCA
GTC AGT GGC CAA AAC CAC ACC TAA TTT GCC TCA
C C AC ;S R 3 - F o r w a r d : T G CT G TT T CC G AC C AG C CA C C
TGA AGG TTT TGG CCA CTG ACT GAC CTT CAG GTC
TGG TCG GAA A; SR3-Reverse: CCT GTT TCC GAC CAG
ACC TGA AGG TCA GTC AGT GGC CAA AAC CTT CAG
GTG GCT GGT CGG AAA C; SR4-Forward: TGC TGA TTA
CTT GGT GGA TGC TGG ATG TTT TGG CCA CTG ACT
GAC ATC CAG CAC ACC AAG TAA T, andSR4-Reverse:CCT
GAT TAC TTG GTG TGC TGG ATG TGT CAG TCA GTG
GCC AAA ACA TCC AGC ATC CAC CAA GTA ATC.L X - 2
cells [11], human HSCs, supplied by Scott L. Friedman, were
cultured in DMEM medium supplemented with 10% fetal
bovine serum at 37◦Ci n5 %C O 2 and were transfected with
10μg of the indicated vectors. Transfected cells were selected
by 5mg/mL blasticidin.
2.3. RT-PCR and Quantitative PCR Analysis of Gene Expres-
sion. Total RNA was extracted from selected LX-2 cells
using Trizol reagent, quantiﬁed by spectrophotometry, and
reverse-transcribed to cDNA using the Invitrogen Reverse
Transcription System. An iCycleriQ Multicolor Real time
PCR (RT-PCR) Detection System (Bio-Rad) was used for
RT-PCR. The cDNA of LX-2 was ampliﬁed using iQ-SYBR
Green Supermix with speciﬁc oligonucleotide primers for
Smad4 and β-actin (for normalization). Gene primers were
Smad4 Forward: 5 -ATT GCC GAC AGG ATG CAG A-3 ;
Reverse: 5 -GAG TAC TTG CGC TCA GGA GGA-3 ; β-actin
Forward: 5 -TCT CTC AAT GGT TTC TGT CCT GTG-
3 ;R e v e r s e :5 -TCC CAT TTC CAA TCA TCC TGC TC-3 .
Threshold cycles (Ct) were automatically calculated by the
RT-PCR System. Each Ct value was normalized to the β-
actin Ct value. Relative quantiﬁcation was expressed as fold-
induction compared to control conditions. PCR ampliﬁca-
tion was performed in a 50μL reaction mixture containing
1 × PCR ampliﬁcation buﬀer, 1.5–2mM MgCl2 (optimized
for each reaction), 25pmol of each primer, 0.2mM dNTPs
and 2.5 units of AmpliTaq DNA polymerase (Perkin Elmer
Applied Biosystem). The PCR program was as follows: 95◦C
for5min,35cyclesof2minat94◦C,1.5minat60◦C,2.5min
at 72◦C, and a ﬁnal extension for 10 seconds at 72◦C. The
PCR products were separated on a 2% agarose gel stained
with ethidium bromide and compared to a standard DNA
size marker.
2.4. Treatment of LX-2 Cells and Preparation of Cell Lysates.
LX-2 cells transfected with SRV4 expressing high levels of
Smad4 RNAi, and a negative control vector, were selected by
blasticidin and cultured in DMEM medium supplemented
with 10% FSC. SA-B (10−6 ML −1) (The concentration is
near to clinical application dose.) was added to LX-2 cellsEvidence-Based Complementary and Alternative Medicine 3
in serum-free medium for 2 days. TGF-β1( 1 0n gm L −1)w a s
added to the medium during the last 2 hours of culture,
or for the last 24h when carrying out gene transfec-
tion examinations. Speciﬁc protein kinase blocker (50μM),
PD98059 (blocking ERK signaling) or SB203580 (blocking
p38 MAPK signaling), was added to the media 30min before
the addition of TGF-β1. After TGF-β1 stimulation, LX-2
cells were washed with PBS and lysed in 50M Tris-HCl,
pH 7.5, 150mM NaCl, 1% Triton X-100, 0.1mM Na3VO4,
1mMPMSF,and0.1mMaprotinin.Celldebriswasremoved
by centrifugation at 15000×gf o r3 0 m i na t4 ◦C. Protein
concentrations were determined using BioRad protein assay.
2.5. Western Blotting. Samples were subjected to 10% so-
dium dodecyl sulphate-polyacrylamide gel electrophoresis
and transferred to nitrocellulose membranes. Membranes
were blocked and washed in TBS-Tween buﬀer. They were
incubated overnight with speciﬁc antibodies (Smad4, β-
Actin, MEK, p38, p-p38, GAPDH, α-SMA or Col. I). After
incubationwithperoxidase-conjugatedsecondaryantibodies
for 1h, membranes were developed with an enhanced chem-
iluminescence western blotting detection system. The exper-
iment was repeated for three times.
2.6. Detection of Collagen I in Media Using ELISA. Cell cul-
ture media were centrifuged and supernatants collected for
measuring total protein concentrations: 90μL sample and
10μL1 0× coating buﬀer (1.59% Na2CO3, 2.93% NaHCO3,
pH 9.6) were added to wells of a 96-well plate in triplicate;
Col. I standard controls were added to standard wells [1 ×
coating buﬀer (0.159% Na2CO3, 0.293% NaHCO3, pH 9.6)].
The 96-well plate was incubated at 4◦Ca n dc o a t e df o r2 4h .
The coating buﬀer was discarded and the plate washed with
washing buﬀer three times for 2 minutes. Rabbit anti-mouse
Col. I (1:200) diluted with 0.01M PBS was added to each
well in a volume of 100μL and incubated at 37◦Cf o r2h .
Goat anti-rabbit IgG-HRP diluted (1:1000) with enzyme-
labeled antibody dilution (90% 0.01M PBS, 10% inactivated
bovineserum)wasaddedtoeachwellina100μLvolumeand
plates were incubated at 37◦C for 2h. The preparations were
developed under darkroom conditions at room temperature.
After the chromatism of the standard well was observable,
2NH 2SO4 (100μL/well) was added to stop the reaction. The
absorbance was read at 492nm on a microplate reader, and a
standard curve was generated. The Col. I contents detected
(ngmL−1) per total protein in the supernatant (mgmL−1)
were recorded.
2.7. Data Analysis. Data are expressed as mean ± standard
deviation. Data were analyzed using a one-way analysis of
variance as well as the least signiﬁcant diﬀerence test, and
P<0.05 was considered statistically signiﬁcant.
3. Results
3.1. Construction of LX-2 Cell-Line Containing Smad4 RNAi.
The Pol II miR RNAi expression vector was constructed and
conﬁrmed by sequencing. The level of Smad4 mRNA in
LX-2 cells transfected with SRV3 and SRV4 was decreased
compared to control cells. After selection of cells with blas-
ticidin, the protein levels of Smad4 in LX-2 cells transfected
with SRV4 were reduced to approximately 30% (Figures 1(a)
and 1(b)). The levels of Smad4 mRNA were reduced to
approximately 70.3% compared to control (Figure 1(b)).
3.2.TheEﬀectofSA-Bonp38MAPKSignalinginLX-2CellsIs
via Inhibiting the Smad and ERK Pathways. Without TGF-β1
stimulation and SA-B drug intervention, p-p38 protein can
be detected in LX-2 cells. When LX-2 cells were transfected
with a negative control plasmid or a SRV4 vector, there was
no signiﬁcant eﬀect on p-p38 protein expression, however,
following to stimulation with TGF-β1 the levels of p-p38
protein were signiﬁcantly increased (P<0.01). The LX-
2 cells containing Smad4 RNAi or Smad4 RNAi combined
with PD98059 expressed higher levels of p-p38 protein when
they were stimulated with TGF-β1( P<0.01). In the case of
LX-2 cells containing Smad4 RNAi, the p-p38 protein ex-
pression levels in LX-2 cells stimulated with TGF-β1w e r e
signiﬁcantly inhibited by SA-B (P<0.001 in all cases)
(Figure 2(a)). Similar eﬀect was observed when LX-2 cells
containing Smad4 RNAi combined with PD98059 addition
(P<0.001 in all cases) (Figure 2(a)).
We determined the changes of α-SMA and Col. I, which
are markers of activated HSCs, following inhibition of the
Smad and ERK pathways. The protein expression of α-SMA
and Col. I was high in control cells and the cells transfected
with a negative control vector, but the levels of protein were
much lower in the SRV4 group. TGF-β1 stimulation of LX-
2 cells increased the protein expression of α-SMA and Col. I
markedly (P<0.01), but the levels were signiﬁcantly lower
in the SRV4 + TGF group (P<0.01) (Figures 2(b) and
2(c)). The Col. I protein content in the supernatants from
these groups showed similar trends (Table 1). In LX-2 cells
containing Smad4 RNAi combined with PD98059 addition
and TGF stimulation, the protein expression of α-SMA was
virtuallyundetectable.InLX-2cellscontainingSmad4RNAi,
combined with TGF-β1 stimulation, the expression of α-
SMA and Col. I was signiﬁcantly inhibited by SA-B or
PD98059 (Figure 2(c)).
3.3. The Eﬀe c to fS A - Bo nE R KS i g n a l i n gi nL X - 2C e l l sI s
via Inhibiting the Smad and p38 Signaling. Our previous re-
search results indicate that SA-B can inhibit the expression
of p-MEK, but have no signiﬁcant eﬀect on other kinases
of ERK pathway [12]. p-MEK was detected in LX-2 cells in
theabsenceofTGF-β1stimulationandSA-Bintervention.p-
MEK level was signiﬁcantly increased by TGF-β1 stimulation
(P<0.001). When Smad signaling was knocked down, p-
MEK expression was signiﬁcantly decreased irrespective of
TGF-β1 stimulation (P<0.01), and there was no statistically
signiﬁcant diﬀerence in p-MEK protein expression in the
S R V 4+T G F+S Bg r o u po rt h eS R V 4+T G Fg r o u p .F u r -
thermore, p-MEK protein was virtually undetectable in the
SRV4 + TGF + SA-B and SRV4 + TGF + SA-B + SB groups
(P<0.001) (Figure 3(a)).
Similar to 3.2, protein expression of α-SMA and Col. I
was detectable in control cells and those transfected with4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Inhibition of Smad4 in LX-2 transfected with Pol II miR RNAi expression vectors (SRV1, SRV2, SRV3, and SRV4). (a) Smad4
mRNA expression levels detected by real time PCR 72h after selection with blasticidin. Results were normalized to Smad4 expression in
“Negative control” using the 2−ΔΔCt method (where Ct is threshold cycle). ∗∗Signiﬁcant diﬀerence versus negative control (n = 3, P<0.01).
On the right side of the ﬁgure is shown the electrophoresis of PCR product. (b) Smad4 protein expression levels detected after selection with
blasticidin, using the Western blot. Blotting with anti-β-actin antibody was conducted as a protein loading control. Quantiﬁcation of the
intensity of bands calibrated to the intensity of total protein bands (means ± SD). ∗∗Signiﬁcant diﬀerence versus negative control (n = 3,
P<0.01).
Table 1: The changes of Col. I in LX-2 cell culture supernatants
following inhibition of ERK and Smad4 signaling pathways.
Group n mean ± S
Control 3 0.567 ± 0.093
Negative control 3 0.469 ± 0.004
SRV4 3 0.351 ± 0.011##
TGF 3 1.007 ± 0.017##
SM4 + TGF 3 0.648 ± 0.012  
SM4 + TGF + SA-B 3 0.289 ± 0.022
SM4 + TGF + PD 3 0.294 ± 0.023∗∗
TGF + SA-B + PD 3 0.439 ± 0.003
SM4 + TGF + SA-B + PD 3 0.252 ± 0.004  
The levels of Col. I protein were determined by ELISA kit as indicated.
Results were expressed as mean ± SE of three independent experiments
performed in triplicate. ##Signiﬁcant diﬀerence versus Control, Negative
control, and SRV4 (n = 3, P<0.01);   Signiﬁcant diﬀerence versus SRV4
and TGF (n = 3, P<0.01); ∗∗Signiﬁcant diﬀerence versus SM4 + TGF
(n = 3, P<0.01);   Signiﬁcant diﬀerence versus SM4 + TGF + SA-B, SM4
+T G F+P D ,a n dT G F+S A - B+P D( n = 3, P<0.01).
a negative control vector, but it was signiﬁcantly lower in
the SRV4 group (P<0.01). LX-2 cells stimulated by TGF-
β1 had signiﬁcantly increased α-SMA and Col. I expression
(P<0.01); and signiﬁcantly reduced α-SMA and Col. I
in the SRV4 + TGF group (P<0.001). LX-2 cells in the
SRV4 + TGF + SB group expressed a low amount of α-SMA
(P<0.01). In the SRV4 + TGF + SA-B group and SRV4 +
TGF + SA-B + SB group, the α-SMA level was minimal. The
protein expression of α-SMA in LX-2 cells of the TGF + SA-
B + SB group was signiﬁcantly lower than that of the TGF +
SA-B group and TGF + SB group (both P<0.01) (Figure
3(b)) . T h el e v e lo fC o l .Ii nt h eS R V 4+T G F+S Bg r o u pa n d
SRV4 + TGF + SA-B group was lower than in the SRV4 +
TGF group (both P<0.0 5 ) .I nt h eS R V 4+T G F+S A - B+
SB group, the protein expression of Col. I was lower than in
t h eS R V 4+T G F+S A - Ba n dT G F+S A - B+S Bg r o u p s( b o t h
P<0.01) (Figure 3(c)). Similar changes of Col. I can be also
observed in culture media of LX-2 (Table 2).
4. Discussion
General TGF-β1 signaling pathways have been described in
detail. In addition to the Smad signaling pathway, TGF-β1
can persistently activate MAPK signaling pathways [13, 14].
A variety of extracellular stimuli transmit signals from cell
membrane to nucleus and converge on MAPK cascades
[15]. Three distinct MAPK pathways have been described in
mammalian cells, the extracellular signal-regulated kinases
(ERK) pathway, the c-Jun amino terminal kinase (JNK)Evidence-Based Complementary and Alternative Medicine 5
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Figure 2: The eﬀects of SA-B on p38 MAPK pathway via Inhibition of ERK and Smad signaling. (a) P38 phosphorylation in LX-2 cells.
The levels of phosphorylated p38 protein were determined by Western blot using anti-phospho-p38 antibodies. The levels of total p38
protein were determined by Western blot using anti-p38 antibodies. Quantiﬁcation of the intensity of bands calibrated to the intensity of
total protein bands (means ± SD). ##Signiﬁcant diﬀerence versus Control, Negative control, and SRV4 (n = 3, P<0.01);    Signiﬁcant
diﬀerence versus SM4 + TGF (n = 3, P<0.001);    Signiﬁcant diﬀerence versus TGF (n = 3, P<0.001); ∗∗∗Signiﬁcant diﬀerence versus
SM4 + TGF + PD (n = 3, P<0.001). (b) α-SMA level in LX-2. The levels of α-SMA protein were determined by Western blot using
anti-α-SMA antibodies. Blotting with anti-GAPDH antibodies was conducted as a protein loading control. Quantiﬁcation of the intensity
of bands calibrated to the intensity of total protein bands (means ± SD). ##Signiﬁcant diﬀerence versus Control, Negative control, and SRV4
(n = 3, P<0.01);   Signiﬁcant diﬀerence versus TGF (n = 3, P<0.01);    Signiﬁcant diﬀerence versus SM4 + TGF (n = 3, P<0.001),
   Signiﬁcant diﬀerence SM4 + TGF + PD and SM4 + TGF + SA-B (n = 3, P<0.001); ∗∗∗Signiﬁcant diﬀerence versus SM4 + TGF +
SA-B, TGF + SA-B + PD (n = 3, P<0.001). (c) Col. I level in LX-2. The levels of Col. I protein were determined by Western blot using anti-
Col. I antibodies. Blotting with anti-GAPDH antibodies was conducted as a protein loading control. ##Signiﬁcant diﬀerence versus Control,
Negative control, and SRV4 (n = 3, P<0.01);   Signiﬁcant diﬀerence versus TGF (n = 3, P<0.01);   Signiﬁcant diﬀerence versus SM4
+T G F( n = 3, P<0.01); ∗Signiﬁcant diﬀerence versus SM4 + TGF + PD, SM4 + TGF + SA-B, and TGF + SA-B + PD (n = 3, P<0.05).
pathway, and the p38 MAPK pathway [16]. TGF-β1a c t i v a t e s
ERK and p38MAPK signaling in HSCs [17, 18].
SA-B inhibits Smads and MAPK activity in HSCs stim-
ulated with TGF-β1[ 8, 19]. However, the mechanism(s) by
which SA-B regulates the MAPK signaling pathway in HSCs
stimulated with TGF-β1 have not been elucidated com-
pletely.
In the present study, we used RNAi to knock down
Smad4 protein expression, thus inhibiting potential cross-
talk of the Smads to the MAPK signaling. The BLOCK-
iT Pol II miR RNAi expression vector system was used to
knock down Smad4 mRNA levels. Smad4 mRNA levels were
decreased by 70.3% in LX-2 cells selected with blasticidin.
This allowed us to investigate the anti-ﬁbrotic action of SA-B
in depth.
4.1. Cross-Talk between the Smad and MAPK Signaling
Pathways. TGF-β1 stimulates further activation of LX-2
cells. Furthermore, phosphorylation of p38 and ERK was
signiﬁcantlyincreased.InLX-2cellsaﬀectedbySmad4RNAi,
the phosphorylation of p38 was not signiﬁcantly diﬀerent
compared to control. However, the protein expression of
p-p38 and p-ERK in LX-2 cells stimulated with TGF-β1
was signiﬁcantly higher than in controls. Smad4 RNAi
did not inhibit the phosphorylation of p38 in LX-2 cells
stimulated with TGF-β1. This suggests there may be lack ofEvidence-Based Complementary and Alternative Medicine 7
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Figure 3: The eﬀects of SA-B on ERK signaling via inhibition of p38 MAPK and Smad signaling. (a) MEK phosphorylation in LX-2 cells.
The levels of phosphorylated MEK protein were determined by Western blot using anti-phospho-MEK antibodies. The levels of total MEK
protein were determined by Western blot using anti-MEK antibodies. Quantiﬁcation of the intensity of bands calibrated to the intensity of
total protein bands (means ± SD). ###Signiﬁcant diﬀerence versus Control, Negative control, and SRV4 (n = 3, P<0.001); ∗∗Signiﬁcant
diﬀerence versus TGF (n = 3, P<0.01);    Signiﬁcant diﬀerence versus SM4 + TGF, SM4 + TGF + SB, and TGF + SA-B + SB (n = 3, P<
0.01). (b) α-SMA levels in LX-2. The levels of α-SMA protein were determined using anti-α-SMA antibodies. Blotting with anti-GAPDH
antibodies was conducted as a protein loading control. ##Signiﬁcant diﬀerence versus Control, Negative control and SRV4 (n = 3, P<0.01);
  Signiﬁcant diﬀerence versus TGF (n = 3, P<0.01);   Signiﬁcant diﬀerence versus SM4 + TGF (n = 3, P<0.01); Signiﬁcant diﬀerence
versus SM4 + TGF (n = 3, P<0.001); ∗∗∗Signiﬁcant diﬀerence versus SM4 + TGF + SB, SM4 + TGF + SA-B, and TGF + SA-B + SB
(n = 3, P<0.001).(c)Col.IlevelinLX-2.ThelevelsofCol.IproteinweredeterminedbyWesternblotusinganti-Col.Iantibodies.Blotting
withanti-GAPDHantibodieswasconductedasaproteinloadingcontrol. ##SigniﬁcantdiﬀerenceversusControl,Negativecontrol,andSRV4
(n = 3, P<0.01);   Signiﬁcant diﬀerence versus TGF (n = 3, P<0.01); ♦Signiﬁcant diﬀerence versus SM4 + TGF (n = 3, P<0.05);
♦♦Signiﬁcant diﬀerence versus SM4 + TGF (n = 3, P<0.01); ∗∗Signiﬁcant diﬀerence versus SM4 + TGF + SB, SM4 + TGF + SA-B, and
TGF + SA-B + SB (n = 3, P<0.01).
“cross-talk” of Smad signaling pathway to the p38 MAPK
signaling pathway in LX-2 cells stimulated with TGF-β1. In
the Smad4 RNAi LX-2 cells with ERK pathway inhibitor,
TGF-β1 induced increased expression of p-p38. This indi-
cates that there seems to be no “cross-talk” between the ERK
signaling pathway and p38 signaling pathway in HSCs. In
Smad4 RNAi LX-2 cells stimulated with TGF-β1, the protein
expression of p-MEK was signiﬁcantly lower compared to
that in the cells without Smad4 RNAi. These results indicate
there may be “cross-talk” between the Smad pathway and the
ERK pathway (Figure 4). Such cross-talk has been reported
in other types of cells [20–22]. In Smad4 RNAi LX-2 cells
stimulated with TGF-β1, SB203580 did not have a signiﬁcant
eﬀect on the expression of p-MEK. This suggests there may
be no signiﬁcant cross-talk between the p38 pathway and
the ERK pathway (Figure 4). However, cross-talk between
ERK and p38 MAPK has been reported in other cell types
[23].Thisindicatesthecomplexityofcross-talkandsignaling
pathways in the diﬀerent cell types.
4.2. The Inhibitory Eﬀe c to fS A - Bo nE R KS i g n a l i n gi nH S C s
Stimulated with TGF-β1. SA-B inhibits the phosphorylation
of MEK in HSCs, but has no signiﬁcant eﬀect on phospho-
rylation of other kinases in ERK signaling. SA-B also has
no signiﬁcant eﬀect on total MEK protein expression [12].
In view of the potential “cross-talk” between the Smad andEvidence-Based Complementary and Alternative Medicine 9
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Figure 4: Proposed mechanisms of the anti-ﬁbrotic eﬀects of SA-B on activated HSCs stimulated by TGF-β1.
Table 2: The changes of Col. I in LX-2 cell culture supernatant after
inhibition of p38 MAPK and Smad4 signaling.
Group n Mean ± S
Control 3 0.567 ± 0.093
Negative control 3 0.469 ± 0.004
SRV4 3 0.351 ± 0.011
TGF 3 1.007 ± 0.017##
SM4 + TGF 3 0.648 ± 0.012  
SM4 + TGF + SA-B 3 0.289 ± 0.022
SM4 + TGF + SB 3 0.281 ± 0.036
TGF + SA-B + SB 3 0.386 ± 0.024∗∗
SM4 + TGF + SA-B + SB 3 0.222 ± 0.026Δ
The levels of Col. I protein were determined by ELISA kit as indicated.
Results were expressed as mean ± SE of three independent experiments
performed in triplicate. ##Signiﬁcant diﬀerence versus Control, Negative
control, and SRV4 (n = 3, P<0.01);   Signiﬁcant diﬀerence versus SRV4
andTGF-β1(n = 3, P<0.01); ∗∗SigniﬁcantdiﬀerenceversusSRV4(n = 3,
P<0.01); ΔSigniﬁcant diﬀerence versus SM4 + TGF + SA-B, SM4 + TGF +
SB, and TGF + SA-B + SB (n = 3, P<0.05).
the ERK signaling pathway, further clariﬁcation of the eﬀect
of SA-B on the ERK signaling pathway was required. To
investigate this, the Smad signaling pathway was inhibited
and the eﬀect of SA-B on the phosphorylation of MEK was
analyzed.
AsshowninFigure 3(a),SA-Bsuppressesthephosphory-
lation of MEK signiﬁcantly. In Smad4 RNAi HSC cells, SA-B
inhibits MEK phosphorylation with or without the addition
of SB203580. This indicates that there is no cross-talk be-
tween the p38 and ERK pathways. The phosphorylation level
of MEK in the SRV4 + TGF group was 50% of that in
the TGF group, and after Smad4 knockdown combined
with SA-B intervention, the phosphorylation level of MEK
was barely detectable by Western blotting. The decline in
phosphorylation levels of MEK in HSCs may not only be due
to the residual levels of Smad4 but also to the action of SA-
B. Therefore, it may be concluded that SA-B directly inhibits
the phosphorylation of MEK in HSCs (Figure 4).
4.3.TheInhibitoryEﬀectofSA-Bonthep38SignalingPathway
in HSCs Stimulated by TGF-β1. MAPK signaling has been
implicated in TGF-β1-mediated signaling and collagen gene
expression [15]. In MAPK family, ERK and p38 MAPK
activation can increase the collagen in hepatic stellate cells.
The data shown in Figures 2(a) and 3(a) illustrate the lack
of cross-talk between p38 MAPK and the Smad or ERK
signaling pathways. The reduction of phosphorylated p38
may be due to SA-B. In previous research we found SA-B has
no signiﬁcant eﬀect on total MEK protein expression [12].
Following Smad4 RNAi and/or blocking ERK signaling,
SA-B inhibits the expression of p-p38 in HSCs stimulated
with TGF-β1. This conﬁrms that SA-B inhibits the phos-
phorylation of p38 in HSCs independent of the Smad and
ERK pathways (Figure 4). To clarify the action of SA-B on
p38MAPK signaling pathway, it will be required to detect the
kinase upstream of p38.
4.4. SA-B Suppresses the Expression of Col. I and α-SMA in
HSCs Stimulated with TGF-β1 via Inhibition of MEK Phos-
phorylation in ERK Signaling and p38MAPK Signaling. The
protein expression of α-SMA can be detected in control cells.
Smad4 RNAi caused a signiﬁcant reduction in the expression
of α-SMA irrespective of TGF-β1 stimulation. Smad4 RNAi
resulted in further reduction in α-SMA expression with ERK
or p38 MAPK signaling being inhibited. In the SRV4 + TGF
+S A - B ,S R V 4+T G F+S A - B+S B ,a n dS R V 4+T G F+S A - B
+ PD groups, the protein expression of α-SMA could not be
detected.10 Evidence-Based Complementary and Alternative Medicine
I nt h eS R V 4+T G F+S A - B ,a n dS R V 4+T G F+P D
groups, the expression of Col. I was inhibited by SA-B, an
eﬀect similar to PD98059. In these groups, the SA-B inhibi-
tory action is weaker than that of Smad4 RNAi, compared to
t h eT G F+S A - B+PDan dS R V 4+T G F+S A - B+PDgr o u p s .
As shown in Figure 3(c), SA-B suppresses the expression of
Col. I more eﬀectively than SB20358 in the SRV4 + TGF +
SA-B and SRV4 + TGF + SB groups. However, in the TGF +
SA-B + SB, SRV4 + TGF + SA-B + SB, SRV4 + TGF + SA-B
andSRV4+TGF+SBgroups,wecouldnotdeterminewhich
was most eﬀective on reducing the production of Col. I in
HSCs in Smad4 RNAi, SB20358, or SA-B.
SA-B has a signiﬁcant inhibitory eﬀe c to nS m a da n d
MAPK signaling. The anti-ﬁbrotic eﬀect of SA-B occurs via
inhibiting p38MAPK signaling pathway directly and inhibit-
ing the cross-talk of Smad signaling pathway to ERK MAPK
signaling pathway.
As demonstrated in Figures 2(c) and 3(c), when the ERK
and p38 MAPK signaling pathways were blocked, respective-
ly, Col. I expression was signiﬁcantly inhibited. Smad4 RNAi
enhanced the inhibitory eﬀect on the intracellular expression
ofCol.I.ThissuggeststhattheSmad,ERK,andp38pathways
are involved in Col. I synthesis in activated HSCs. However,
Smad4 RNAi (70.3% eﬀective) and antagonists of ERK and
p38 MAPK did not completely inhibit signal transduction in
LX-2 cells stimulated with TGF-β1, and LX-2 cells express
residual levels of Col. I protein. After weakening the Smad
and MAPK signal pathways, the inhibitory action of SA-B on
Col. I production is still evident. The expression of Col. I is
the lowest in the SRV4 + TGF + PD + SB + SA-B group, but
it can still be detected. A possible explanation for this result
is that SA-B supplements the inhibitory action of Smad4
RNAi, PD98059, and SB203580 on the signal transduction
pathway, but does not completely inhibit Col. I synthesis in
HSCsstimulatedwithTGF-β1,suggestingtheinvolvementof
other signal transduction pathways. Normally cultured LX-
2 cells express Col. I, suggesting that they are activated by
mechanisms other than TGF-β1 stimulation, which requires
further investigation.
Appendix
ECM: Extracellular matrix
CCl4: Carbon tetrachloride
Col. I: Collagen type I
HSCs: Hepatic stellate cells
MFB: Myoﬁbroblast-like cells
TGF-β1: Transforming growth factor-β1
α-SMA: α-smooth muscle actin
MAPK: Mitogen-activated protein kinase
SA-B: Salvianolic-acids B
SB: SB203580
PD: PD98059
SRV4: Smad4 RNAi
ERK: Extra cellular signal-regulated kinase
p38 MAPK: p38 mitogen-activated
RNAi: RNA interference
miRNA: MicroRNA
pri-miRNA: Primary transcript of miRNA
p-MEK: Phosphorylation of MEK
p-p38: Phosphorylation of p38
p-MKK3/6: Phosphorylation of MKK3/6.
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